IES Holdings Closes $691 Million DBM Global Acquisition
IES Holdings completed its acquisition of DBM Global for about $691 million on October 5, a deal that reshapes the contractor's business and financing profile as it competes with larger rival EMCOR Group in data-center construction. The consideration included $545 million of cash and 430,974 IES shares valued at roughly $146 million, with the cash portion funded by cash on hand and credit-facility borrowings, meaning June's debt-free balance sheet no longer describes the company. DBM adds structural steel engineering, fabrication and erection with about $1.5 billion of trailing revenue, and IES reported fiscal third-quarter revenue rose 40% to $1.24 billion, with communications revenue up 51% to $453.1 million. EMCOR, meanwhile, reported second-quarter revenue of $5.15 billion, up 19.8%, earnings of $9.06 per share, up 34.8%, and remaining performance obligations of $17.14 billion, up 43.9%, while raising full-year earnings guidance to $32 to $33.25 per share. At October 5 prices, consensus forward earnings multiples were about 22 times for EMCOR and 27 times for IES, though the IES figure may not reflect every acquisition effect.
Artificial Intelligence › Build-out, Construction & Engineering ▲Competition
Artificial Intelligence › AI Data Center & Build-out ▲Competition
Energy Transition & Power Demand › Grid, Transmission & Power Equipment Competition
IESC · Capital · Positive IES closed its $691M DBM Global acquisition, funded by cash and credit borrowings, reshaping its business and financing profile.
IESC · Demand · Positive IES reported fiscal Q3 revenue up 40% to $1.24B with communications revenue up 51% to $453.1M.
DBMG · Capital · Neutral DBM Global is the acquisition target, being bought by IES for ~$691M; impact on DBM itself is not clearly positive or negative.
EME · Competition · Neutral EMCOR is cited as the larger rival IES competes with in data-center construction, and its strong Q2 results are reported for comparison.
IES Holdings to Acquire DBM Global for $650 Million
IES Holdings, Inc. has announced a definitive agreement to acquire DBM Global from INNOVATE Corp. for approximately $650 million in combined cash and stock, with total consideration reaching $685 million including minority interest buyouts and tax election payments. IES Holdings reported stellar fiscal Q3 2026 results, with revenue surging 40% year-over-year to $1.24 billion and net income nearly doubling to $153.0 million, while ending the quarter debt-free with $77.3 million in cash and $310.6 million in marketable securities. The company's backlog reached a record $4.5 billion, and its board authorized a two-for-one stock split. INNOVATE Corp.'s Q2 2026 results showed consolidated revenue climbing 74.2% to $421.6 million, but DBM Global accounted for $414.0 million of that revenue and $48.7 million of total Adjusted EBITDA, highlighting its dependence on the unit being sold. The $545 million cash proceeds from the sale will allow INNOVATE to de-lever its balance sheet, but its remaining operations, Spectrum and Life Sciences, remain unprofitable or cash-starved. Hedge fund data shows stronger conviction in IES Holdings, with ownership increasing from 34 to 39 funds, while INNOVATE saw a rise from five to eight funds.
INNOVATE Q2 Revenue Surges 74% to $421.6 Million on Record Infrastructure Performance
INNOVATE Corp. reported second-quarter 2026 revenue of $421.6 million, a 74.2% increase from a year earlier, driven by record results in its Infrastructure segment. Net income attributable to common and participating preferred stockholders reached $10.4 million, or $0.71 per fully diluted share, compared with a net loss of $22 million, or $1.67 per share, in the prior-year quarter. Consolidated adjusted EBITDA rose to $46.3 million from $15.7 million. The Infrastructure segment, led by DBM Global, posted record quarterly revenue of $414 million and adjusted EBITDA of $48.7 million, with reported backlog growing to $1.9 billion and adjusted backlog reaching $2.7 billion. Broadcasting entered a definitive agreement for CONX Corp. to acquire a controlling interest of about 75%, while Life Sciences revenue fell 31.3% to $2.2 million amid weaker R2 sales and liquidity constraints.
United States